Seattle Genetics, Inc. SGEN shares were seen trading lower by $8.68 at $53.18 in Tuesday's morning session. The catalyst for the decline is the announcement that a clinical hold has been placed on Phase 1 trial of Vadastuximab Talirine.
Market News and Data brought to you by Benzinga APIsAfter a much lower open, it bottomed at $52.18 and managed a brief rally to $54.70 before resuming its move lower. It has fallen back to the $53 area, but has yet to make a new low for the session.
If the decline continues through the current low there may be additional support at its November 1 low ($51.50) as well as its October 31 low ($50.80).
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in